Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 8/20 | 0.58 |
| ▸ | PDE4A | P27815 | 8/20 | 0.58 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.58 |
| ▸ | PDE4C | Q08493 | 8/20 | 0.58 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | GMNN | O75496 | 1/20 | 0.58 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.58 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.53 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20908833 | 0.92 | STING1 (0.67) | STING1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL20908500 | 0.86 | STING1 (0.59) | STING1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL24323072 | 0.85 | STING1 (0.72) | STING1PDE3BPDE3A | |
| SCHEMBL24322083 | 0.85 | STING1 (0.71) | STING1LMNAGMNNRAPGEF3BLM | |
| SCHEMBL20908476 | 0.84 | STING1 (0.82) | STING1PDE3BPDE3A | |
| SCHEMBL20547873 | 0.82 | STING1 (0.77) | STING1LMNAGMNNRAPGEF3BLM | |
| SCHEMBL24323065 | 0.81 | STING1 (0.76) | STING1LMNAGMNNRAPGEF3BLM | |
| SCHEMBL25691261 | 0.81 | STING1 (0.76) | STING1LMNAGMNNRAPGEF3BLM | |
| SCHEMBL20908440 | 0.80 | STING1 (0.72) | STING1LMNAGMNNRAPGEF3BLM | |
| SCHEMBL24687500 | 0.79 | STING1 (0.78) | STING1PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220117995-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220117995-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | DPYD, CD38, DUT | STING1 159/4885PDE4A 160/4885PDE4B 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.